Skip to content
Evigrade
ModerateGlucocorticoids×5-HT3 serotonin receptor antagonist

Updated · Methodology

Mechanism

Ondansetron prolongs the QT interval in a dose-dependent way, and postmarketing cases of torsade de pointes have been reported (ondansetron summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk is higher with low potassium and magnesium. For this reason, caution is needed with drugs that disturb the electrolyte balance (ondansetron SmPC, AEMPS). Dexamethasone increases potassium excretion, and potassium loss can cause arrhythmias. With high doses of dexamethasone, potassium supplements and blood potassium monitoring are needed (dexamethasone SmPC, AEMPS). Dexamethasone induces the enzyme CYP3A4 and may lower the levels of drugs that CYP3A4 breaks down (dexamethasone label, US Food and Drug Administration, FDA). Three liver enzymes break down ondansetron, CYP3A4, CYP2D6 and CYP1A2, and even with strong CYP3A4 inducers the rise in its clearance is not considered clinically relevant (ondansetron SmPC, AEMPS, and ondansetron FDA label).

Symptoms

QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes causes palpitations, dizziness and fainting. Among cardiac reactions, ondansetron uncommonly causes arrhythmias, chest pain and slow heart rate, and rarely QTc prolongation including torsade de pointes (ondansetron summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Potassium loss during dexamethasone treatment can cause arrhythmias (dexamethasone SmPC, AEMPS). Low potassium usually shows as muscle weakness and muscle cramps.

Management

The combination is acceptable. In the ondansetron summary of product characteristics (SmPC), dexamethasone is part of the regimens for preventing chemotherapy-induced vomiting, and dexamethasone is indicated for preventing and treating cytostatic-induced nausea and vomiting as part of antiemetic regimens (ondansetron and dexamethasone SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In highly emetogenic chemotherapy, a single oral dose of 24 mg ondansetron with 12 mg oral dexamethasone sodium phosphate can be given 1–2 hours before chemotherapy. A single intravenous dose of 20 mg dexamethasone sodium phosphate can be added to intravenous ondansetron before chemotherapy (ondansetron SmPCs, AEMPS). The dexamethasone antiemetic schedule is 10–20 mg before chemotherapy, then 4–8 mg 2–3 times a day for 1–3 days in moderately emetogenic chemotherapy, or up to 6 days in total in highly emetogenic chemotherapy, if needed (dexamethasone SmPC, AEMPS). Correct low potassium and magnesium before giving ondansetron (ondansetron SmPC, AEMPS). In patients with electrolyte disturbances, heart failure or slow heart rate, and in those taking other QT-prolonging drugs, use ondansetron with caution and monitor the electrocardiogram (ECG) (ondansetron SmPC, AEMPS, and ondansetron label, US Food and Drug Administration, FDA). With high doses of dexamethasone, give potassium supplements, restrict salt and monitor blood potassium (dexamethasone SmPC, AEMPS, and dexamethasone FDA label). Do not give a single intravenous ondansetron dose above 16 mg, because the QT risk grows with the dose. In patients aged 75 or older, the first intravenous dose should not exceed 8 mg (ondansetron injection SmPC, AEMPS). Do not change the ondansetron dose because of dexamethasone: even with strong CYP3A4 inducers, ondansetron needs no dose adjustment (ondansetron FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dexamethasone

Other interactions with Ondansetron